New Hope for Lp(a): Phase 3 Pelacarsen Data Now Expected in First Half of 2026
Lipoprotein(a), or Lp(a), has become one of the hottest topics in the longevity and preventive cardiology space. More and more health-conscious individuals are getting their Lp(a) levels measured as part of advanced cardiovascular risk assessment. The problem? Until now, there have been no approved therapies specifically designed to lower it.
That may soon change.
On January 31, 2025, Ionis Pharmaceuticals’ partner Novartis provided an important update on pelacarsen, an investigational antisense oligonucleotide therapy specifically designed to reduce Lp(a) levels. According to Novartis’ year-end earnings report, the Phase 3 Lp(a)HORIZON cardiovascular outcomes study is now expected to deliver results in the first half of 2026, with potential regulatory submissions planned for the second half of 2026.
The slight delay is driven by the rate of blinded cardiovascular events accumulating in the large, event-driven trial, which has enrolled more than 8,000 patients. Ionis remains highly confident in both the drug and the study’s ability to demonstrate meaningful benefit for patients with elevated Lp(a) and established cardiovascular disease.
Why This Matters for Longevity
Elevated Lp(a) is a genetically determined, independent risk factor for heart disease, stroke, and aortic valve stenosis. It’s estimated that more than eight million people worldwide have both elevated Lp(a) and cardiovascular disease. Unlike LDL cholesterol, Lp(a) has been notoriously difficult to modify through lifestyle or existing medications.
Pelacarsen, discovered by Ionis and licensed to Novartis in 2019, works by targeting the genetic messenger responsible for producing apolipoprotein(a), the key component of Lp(a) particles. If successful, the Lp(a)HORIZON trial will be the first cardiovascular outcomes study to show whether lowering Lp(a) directly reduces major cardiovascular events.
For those of us focused on extending healthspan and staying young, this is exciting news. While we wait for the data, getting your Lp(a) measured (it’s a simple blood test) is a smart move, especially if you have a family history of early heart disease. Awareness is the first step—effective treatment may be closer than we thought.
Stay tuned. The longevity field is moving fast, and pelacarsen could become a game-changer for millions.
